Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did 😎Read how

Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

Published 22/09/2022, 12:27
© Reuters. Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

  • Inventiva (NASDAQ: IVA) and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan.
  • Inventiva will receive an upfront payment of $12 million, and $5 million are also expected in the short term if certain clinical milestones are met. Inventiva has the potential to receive up to $290 million in milestone payments.
  • Related: FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients.
  • In its 1H earnings release, Inventiva said it targets the last patient's first visit for NATiV3 Phase 3 trial of lanifibranor in patients with NASH for H2 2023 vs. 1H 2023, with topline data from part 1 of the study now targeted for 2H of 2025.
  • The company says the delay is primarily due to a higher than initially projected screen failure rate resulting in a slower than anticipated enrollment rate hit by the Russia-Ukraine war and the pandemic.
  • With a cash balance of €76.4 million, Inventiva's Cash runway extended through Q4 2023, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility.
  • Price Action: IVA shares trading higher by 22.10% higher at $4.80 during premarket trading on Thursday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.